Dr. Nadia Giannetti trained at McGill and Stanford University. She is an attending Cardiologist and an Associate Professor at McGill. She is the Medical Director of the Heart Failure and Transplant Program at the MUHC. She is a co-author of several Canadian Heart Failure and Heart Transplant Guidelines. She has led multiple clinical trials as a local PI. She is the former Chief of Cardiology and is presently the Associate Physician-in-Chief (Department of Medicine) at the MUHC.

Natalie Gendron is the lead research nurse for the Courtois Cardiovascular Signature clinical team and Project Manager for Heart-in-a-Dish protocol. She has been involved in multiple cardiovascular clinical trials with pharmaceuticals as well as local investigators. She is involved in patient recruitment, data review and the liaison with Dr. Cecere and Dr. Hebert’s research teams.

Dr. Sonya Hui is a Cardiology resident physician at McGill University. She completed her MSc and PhD at the University of Toronto and postdoctoral fellowship at the University of Ottawa Heart Institute in cardiovascular scientific research. Her academic interests include translational cardiovascular research and personalized medicine.

Abigail Sousa is a Clinical research coordinator, recruits patients with passion and charisma. She ensures all research participants have a good understanding of the protocol, have their questions answered and feel valued by participating in this project.

Leila Haririsanati is a clinical research coordinator and MD from Iran. She is passionate about patient care. She approaches people with kindness, recruits patients and collects samples for the protocol.

Dr. Cecere is a cardiac surgeon at the McGill University Health Centre and his research program focuses on the prevention of cardiac disease and cardiac repair. His laboratory’s work involves studying cell-free therapies, elucidating personalized treatments for patients with heart disease, as well as gaining a better understanding of the underlying causes of patient-specific responses to injury.

Ida’s  work investigates patient-specific differences after injury and drug-mediated recovery in iPSC-derived cardiomyocytes from healthy donors and cardiomyopathic patients.

Elise is a detail-oriented and dedicated member of Dr. Cecere’s laboratory, who is responsible for the reprogramming of patient-derived stem cells and heart cells.

Jeremy’s research  aims to improve our understanding of the factors secreted by induced pluripotent stem cell derived from cardiomyopathy patients and healthy controls.

Dr. Kashif Khan is a Vanier Scholar and has published >20 articles about atherosclerosis, cardiac regeneration, and stem cell biology. As a future clinician-scientist, he is passionate about translating research from bench to bedside.

Since 2021, David has been training in creating lab-grown cardiomyocytes. His project investigates the role of mitochondria and cell death in hypoxia-mediated cardiac damage, bridging his clinical zeal as a medical student with his lifelong passion for research and discovery.

Patrick is an Honours kinesiology student with a minor in biotechnology at McGill University. He has been a member of the team since 2021 and is currently researching the cardiotoxic effects and unique patient-cardiomyocyte responses to Doxorubicin.

Janice is a student at McGill University, majoring in Pharmacology and minoring in Entrepreneurship. She initiated the iPSC-derived endothelial cells project at the lab and is working on a comprehensive patient-specific hypoxic disease model.

Dr. Hébert has a long track record in understanding the biology of key signalling proteins in cardiovascular disease. His lab’s new focus on induced pluripotent stem cells iPSCs for DCM disease modelling has opened productive new vistas for their work to understand disease progression in individual patients.

Karima’s  project focuses on generating and testing viral versions of the biosensors in iPSC-derived cardiomyocytes to determine how cell context affects signaling.

Kyla’s research focuses on exploring cellular signalling in health and disease using iPSC-derived cardiomyocytes derived from healthy volunteers and patients diagnosed with idiopathic dilated cardiomyopathy.

Cara’s project focuses on using iPSC-derived heart muscle cells from dilated cardiomyopathy patients and healthy controls to characterize features of disease.

Alyson is a Master’s student in the Hébert Lab working on characterizing morphological differences between patient-derived iPSC-cardiomyocytes and enhancing their maturity.

Grace’s project uses iPSC-derived cardiac fibroblasts to examine cellular signalling in the fibrotic response, a key process in dilated cardiomyopathy pathogenesis.